Kamari Pharma Secures $23M Series A to Advance Rare Genetic Skin Disease Therapies

David Aviezer, Kamari Pharma CEO

Kamari Pharma, a privately-held clinical stage biotechnology company developing first and best-in-class treatments for rare and severe genetic skin diseases, today announced the closing of a $23 million Series A financing. The round was co-led by new investor BRM Group and existing investor Pontifax with participation from additional investors.

Proceeds will be used to advance Kamari's lead program KM023, a first-in-class oral TRPV3 inhibitor, into clinical development for the treatment of three rare genetic skin diseases, Olmsted syndrome, severe keratoderma and ichthyosis. The Company plans to initiate proof-of-concept clinical trials for each of these indications. The Olmsted syndrome study will commence first, in the second half of 2025, with top-line results anticipated by year-end.

David Aviezer, PhD, MBA, Chief Executive Officer of Kamari Pharma, said: "The backing of BRM and Pontifax is a testament to the potential of our oral TRPV3 inhibitor to become a first- and best-in-class treatment for several rare genetic skin diseases. Coupled with strong preclinical data, this investment allows us to accelerate the development of KM023 and generate data in Olmsted syndrome patients by the end of the year."

Alon Maor, Partner at BRM Group, commented: "Kamari's approach of inhibiting TRPV3, a key regulator in skin disease, differentiates the Company in the rare dermatology space. We are looking forward to working alongside Kamari's experienced board of directors and team, leveraging their extensive track record in rare disease drug development to bring novel, safe and effective treatments to patients."

---

Send us your press releases to shareyournews@lucidityinsights.com